SEC Form 4 · accession 0001127602-18-001820
Elevance Health, Inc. · ELV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Swedish
Officer — Executive Chairman · Director
Period of report
Jan 11, 2018
Accepted (ET)
Jan 16, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001156039
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 11, 2018 | M | 67,500 | $89.44 | A | 134,043 | D | |
| Common StockF2 | Jan 11, 2018 | S | 7,278 | $234.73 | D | 126,765 | D | |
| Common StockF3 | Jan 11, 2018 | S | 23,364 | $235.58 | D | 103,401 | D | |
| Common StockF4 | Jan 11, 2018 | S | 36,858 | $236.28 | D | 66,543 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5 | $89.44 | Jan 11, 2018 | M | 67,500 | D | — | Mar 3, 2021 | Common Stock | 67,500 | 46,600 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 2, 2017, as modified on December 11, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $234.04 to $234.99. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $235.04 to $236.03. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $236.04 to $236.79. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The option represents a right to purchase a total of 114,100 shares, and is exercisable in six semi-annual installments, with two installments of 19,016 shares each and four installments of 19,017 shares each, beginning on September 3, 2014, which is the six-month anniversary of the option grant date.